Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2011-10-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01460836
Assess Increased Mortality Risk With Each Year of Delayed Tobramycin Solution (TIS) Initiation, and Effect of TIS on Mortality Across Study Centers
Withdrawn
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01460849
Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
Phase 2
Terminated
- Conditions
- Transfusion-dependent β-thalassemia PatientsCardiac Iron Overload
- Interventions
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01459718
- Locations
- 🇬🇷
Novartis Investigative Site, Patras, Greece
Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01459250
- Locations
- 🇺🇸
Novartis Investigative Site, Knoxville, Tennessee, United States
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
Phase 1
Completed
- Conditions
- Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2011-10-21
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT01456676
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2011-10-21
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT01456689
- Locations
- 🇪🇸
Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain
A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects
- First Posted Date
- 2011-10-21
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT01456663
- Locations
- 🇭🇺
Novartis Investigative Site, Balatonfured, Hungary
Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2012-07-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01451450
Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients
Phase 2
Completed
- Conditions
- Erythemato-telangiectatic Rosacea
- Interventions
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01449591
- Locations
- 🇺🇸
Novartis Investigative Site, Spokane, Washington, United States
Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients
Phase 1
Completed
- Conditions
- HypertensionChronic Kidney DiseaseNephrotic Syndrome
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT01447485
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath